TMB or not TMB as a biomarker: That is the question

医学 彭布罗利珠单抗 肿瘤科 生物标志物 癌症 内科学 肺癌 免疫疗法 疾病 生物 遗传学
作者
Alfredo Addeo,Alex Friedlaender,Giuseppe Luigi Banna,Glen J. Weiss
出处
期刊:Critical Reviews in Oncology Hematology [Elsevier BV]
卷期号:163: 103374-103374 被引量:205
标识
DOI:10.1016/j.critrevonc.2021.103374
摘要

Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic options for many cancers. These treatments have demonstrated improved efficacy and often a more favourable toxicity profile compared to standard cytotoxic chemotherapy. There are considerable differences among responders, with some patients experiencing durable long-term disease control and even remission. Given this variability, determining a proper biomarker to select patients for ICI therapy has become increasingly important. The only biomarker proven to be predictive of overall survival benefit with ICI therapy is PD-L1 expression level measured by immunohistochemistry. Several attempts have been made to identify different predictive biomarkers. One of the most intriguing and divisive is tumor mutational burden (TMB). TMB represents the number of mutations per megabase (Mut/Mb) of DNA that were sequenced in a specific cancer. With a higher number of mutations detected, and consequentially an increase in the number neo-epitopes, then it is more likely that one or more of those neo-antigens could be immunogenic and trigger a T cell response. Initially, TMB was identified as a biomarker for ICIs in melanoma and subsequent studies suggested a possible clinical role for TMB in non-small cell lung cancer. The initial data were not confirmed in a prospective study assessing OS as the primary endpoint. Recently, the FDA has approved pembrolizumab in all cancers with a TMB > 10Mut/Mb[12] based on findings from the phase 2 KEYNOTE-158. Much criticism has emerged about this pan-cancer approval, in particular about the use of TMB as biomarker to select patients. Here we review the data about the importance and role of TMB as possible pan-cancer one-size-fits-all biomarker. We highlight the strengths and intrinsic limitations of such a complex biomarker and its adoption in the daily practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乖咪甜球球完成签到 ,获得积分10
1秒前
季末默相依完成签到,获得积分10
2秒前
4秒前
yiyi完成签到 ,获得积分10
4秒前
活力的鹰完成签到 ,获得积分10
4秒前
sea完成签到 ,获得积分10
6秒前
wzk完成签到,获得积分10
8秒前
linpeng发布了新的文献求助10
9秒前
LaixS完成签到,获得积分0
10秒前
要笑cc完成签到,获得积分0
12秒前
顺心妙之完成签到 ,获得积分10
12秒前
dktrrrr完成签到,获得积分10
13秒前
宣宣宣0733完成签到,获得积分0
14秒前
胡质斌完成签到,获得积分0
16秒前
维C完成签到 ,获得积分10
17秒前
大明发布了新的文献求助10
19秒前
CX完成签到,获得积分10
20秒前
20秒前
华仔的应助被科研通管家采纳,获得10
21秒前
NexusExplorer的应助被科研通管家采纳,获得10
21秒前
21秒前
不安碧灵完成签到,获得积分10
24秒前
linpeng完成签到,获得积分10
24秒前
宋艳芳完成签到,获得积分10
27秒前
快乐的幼丝完成签到 ,获得积分0
27秒前
香蕉觅云的应助被大明采纳,获得10
28秒前
CHEN完成签到 ,获得积分10
31秒前
驰骋完成签到 ,获得积分10
32秒前
maple完成签到 ,获得积分10
32秒前
阿冰完成签到 ,获得积分10
33秒前
酷炫映阳完成签到 ,获得积分10
34秒前
怡然的千儿完成签到,获得积分10
35秒前
大明完成签到,获得积分10
36秒前
harden9159完成签到,获得积分10
37秒前
41秒前
仁仁仁完成签到,获得积分10
42秒前
灯座完成签到,获得积分10
44秒前
u雨发布了新的文献求助10
45秒前
Voiceless的应助被Bin_Liu采纳,获得10
48秒前
不吃压力就是干完成签到 ,获得积分10
48秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808758
捐赠科研通 7776098
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012